Could cause temporary or reversible harm; serious harm is unlikely.
Superpotent Drug: The 3-month stability result for assay was found to be above specification limit
| Brand name | ISOTRETINOIN |
| Generic name | ISOTRETINOIN |
| Active ingredient(s) | ISOTRETINOIN |
| Distributed by / for | Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. Blister Pack |
| NDC | 0591-2436-45 |
| Full product label | Isotretinoin Capsules, USP 40mg, 30-count 3x10 blister packs per carton, Rx Only, Manufactured For: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054. Blister Pack NDC 0591-2436-45, Carton NDC 0591-2436-15 |
| Recalling firm | Teva Pharmaceuticals USA, Inc |
| Distribution | Nationwide in the USA |
| Quantity | 5,304 3x10-cartons |
| Recall initiated | 2024-03-28 |
| Report date | 2024-04-17 |
| Recall completed | — |
| Recall number | D-0439-2024 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Parsippany NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗